Product news

Share this article:
Products
The FDA approved GlaxoSmithKline's Advair Diskus 250/50 (fluticasone propionate 250 mcg and salmeterol 50 mcg inhalation powder) for the reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD). With this approval, Advair becomes the only treatment FDA has approved to reduce COPD exacerbations. 

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions